1. Home
  2. FIEE vs BCDA Comparison

FIEE vs BCDA Comparison

Compare FIEE & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo FiEE Inc

FIEE

FiEE Inc

HOLD

Current Price

$3.50

Market Cap

15.6M

Sector

Utilities

ML Signal

HOLD

BCDA

BioCardia Inc.

HOLD

Current Price

$1.27

Market Cap

14.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FIEE
BCDA
Founded
N/A
N/A
Country
United States
United States
Employees
43
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
15.6M
14.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
FIEE
BCDA
Price
$3.50
$1.27
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$25.00
AVG Volume (30 Days)
N/A
99.9K
Earning Date
N/A
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
N/A
$1.00
52 Week High
N/A
$3.20

Technical Indicators

Market Signals
Indicator
FIEE
BCDA
Relative Strength Index (RSI) 75.27 44.90
Support Level $2.51 $1.16
Resistance Level $3.56 $1.34
Average True Range (ATR) 0.22 0.09
MACD 0.07 -0.01
Stochastic Oscillator 95.24 32.79

Price Performance

Historical Comparison
FIEE
BCDA

About FIEE FiEE Inc

FiEE Inc, formerly Minim Inc is a digital service provider focused on integrating artificial intelligence and data analytics into content creation and brand management. The company offers a range of services designed to support creators, artists, and businesses in developing, managing, and optimizing their digital presence across various platforms, including customized graphic and posts, short videos, and editorial calendars aligned with brand goals.

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

Share on Social Networks: